Surmodics to Participate in Upcoming Investor Conferences in March
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--#InVitroDiagnostic--Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that management will participate in the following upcoming investor conferences:
The 33rd Oppenheimer Annual Healthcare Conference, which is being held virtually March 13‑15, 2023.
- Management will present on Wednesday, March 15, at 10:40 a.m. ET (9:40 a.m. CT).
The Sidoti Small-Cap Conference, which is being held virtually March 22-23, 2023.
- Management will participate in 1x1 meetings with investors on Wednesday, March 22, and Thursday, March 23. There will be no formal presentation.
To access a live webcast of the presentation, go to “Events & Presentations” under the “Investors” section of the Company’s website at https://surmodics.gcs-web.com/events-and-presentations, and click on the webcast icon under “Upcoming Events.” A replay of the webcast will be archived on the website for the following 90 days.
About Surmodics, Inc.
Surmodics is a leading provider of performance coating technologies for intravascular medical devices and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays. Surmodics also develops and commercializes highly differentiated vascular intervention medical devices that are designed to address unmet clinical needs and engineered to the most demanding requirements. This key growth strategy leverages the combination of the Company’s expertise in proprietary surface modification and drug-delivery coating technologies, along with its device design, development, and manufacturing capabilities. The Company’s mission is to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com. The content of Surmodics’ website is not part of this press release or part of any filings that the company makes with the Securities and Exchange Commission.
Surmodics Investor Inquiries:
Jack Powell, Investor Relations